Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

1,050 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “However, some cardioprotective and vasodilatory actions of GLP-1 are preserved in GLP-1R( / ) mice after ischemia/reperfusion (Ban et al., 2008) and are thought to be mediated, at least in part, by its insulinotropically inactive metabolite, GLP-1 (9-36) (Ban et al., 2008; Sonne et al., 2008),…”
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024, background): “469 Importantly, the “ GLP-1-carotid body pathway ” may represent a novel therapeutic target for managing cardiovascular metabolism and treating patients with diabetes and hypertension who exhibit heightened sympathetic activity.”
Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies (2018, background): “It was also reported that GLP-1 receptors are expressed on vascular endothelial cells and directly increase the production of NO and restrict the expression of endothelial cell adhesion factors [124, 125].”
Research Progress on the Relationship between Atherosclerosis and Inflammation (2018, background): “Glucagon-like peptide-1 contributes to glucose homeostasis by stimulating insulin secretion in pancreatic β cells, and also exerts cardioprotective and vasodilatory actions [74,75].”